Detalhe da pesquisa
1.
Loss of GABARAP mediates resistance to immunogenic chemotherapy in multiple myeloma.
Blood
; 2024 Mar 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38551812
2.
A MIR17HG-derived long noncoding RNA provides an essential chromatin scaffold for protein interaction and myeloma growth.
Blood
; 141(4): 391-405, 2023 01 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-36126301
3.
Transcriptome Analysis of Diffuse Large B-Cell Lymphoma Cells Inducibly Expressing MyD88 L265P Mutation Identifies Upregulated CD44, LGALS3, NFKBIZ, and BATF as Downstream Targets of Oncogenic NF-κB Signaling.
Int J Mol Sci
; 24(6)2023 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36982699
4.
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92.
Blood
; 132(10): 1050-1063, 2018 09 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29997223
5.
Multiple myeloma: the (r)evolution of current therapy and a glance into future.
Haematologica
; 105(10): 2358-2367, 2020 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33054076
6.
Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma.
Blood
; 129(16): 2233-2245, 2017 04 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-28096095
7.
DAMPening Tumor Immune Escape: The Role of Endoplasmic Reticulum Chaperones in Immunogenic Chemotherapy.
Antioxid Redox Signal
; 2024 Mar 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38366728
8.
Epigenetic regulation of CD38/CD48 by KDM6A mediates NK cell response in multiple myeloma.
Nat Commun
; 15(1): 1367, 2024 Feb 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38355622
9.
Venetoclax resistance leads to broad resistance to standard-of-care anti-MM agents, but not to immunotherapies.
Blood Adv
; 2024 Jun 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38861273
10.
BCMA-targeted bortezomib nanotherapy improves therapeutic efficacy, overcomes resistance, and modulates the immune microenvironment in multiple myeloma.
Blood Cancer J
; 13(1): 184, 2023 12 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38072962
11.
BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma.
Clin Cancer Res
; 29(9): 1807-1821, 2023 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36780189
12.
Promises and Challenges of Immunogenic Chemotherapy in Multiple Myeloma.
Cells
; 11(16)2022 08 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36010596
13.
Therapeutic activation of G protein-coupled estrogen receptor 1 in Waldenström Macroglobulinemia.
Exp Hematol Oncol
; 11(1): 54, 2022 Sep 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36096954
14.
CRISPR Interference (CRISPRi) and CRISPR Activation (CRISPRa) to Explore the Oncogenic lncRNA Network.
Methods Mol Biol
; 2348: 189-204, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34160808
15.
Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation.
Blood Cancer Discov
; 2(5): 468-483, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34568832
16.
ROBO1 Promotes Homing, Dissemination, and Survival of Multiple Myeloma within the Bone Marrow Microenvironment.
Blood Cancer Discov
; 2(4): 338-353, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34268498
17.
Harnessing the Immune System Against Multiple Myeloma: Challenges and Opportunities.
Front Oncol
; 10: 606368, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33585226
18.
The Non-Coding RNA Landscape of Plasma Cell Dyscrasias.
Cancers (Basel)
; 12(2)2020 Jan 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-32019064
19.
Mesenchymal stem cells: paving the way for myeloma onset?
Blood Adv
; 8(10): 2573-2574, 2024 May 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38805218
20.
Editor's Note: A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells.
Clin Cancer Res
; 30(10): 2288, 2024 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38745477